Electra Therapeutics Advances ELA026 in Pivotal Trial for Rare Blood Disorder sHLH
Key Insights
Electra Therapeutics (search) presented data on ELA026, the first investigational therapy designed to treat secondary hemophagocytic lymphohistiocytosis (search) (sHLH (search)) regardless of underlying trigger at ASH 2025.
The SURPASS Phase 2/3 pivotal study is evaluating ELA026's safety and efficacy in newly diagnosed adult and pediatric sHLH (search) patients across academic centers in the U.S. and Europe.
A natural history study of 232 adult patients over 16 years highlighted sHLH (search)'s devastating prognosis, with malignancy-associated cases showing approximately 50% mortality at two months.
Electra Therapeutics (search) presented compelling data on its lead investigational therapy ELA026 for secondary hemophagocytic lymphohistiocytosis (search) (sHLH (search)) at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. The company showcased both its pivotal SURPASS trial design and real-world evidence highlighting the critical unmet need in this rare, life-threatening hyperinflammatory disease.
Novel Mechanism Targets Root Cause of Disease
ELA026 represents the first investigational therapy designed to treat sHLH (search) regardless of underlying trigger, leveraging a novel mechanism of action that targets signal regulatory proteins (search) (SIRP (search)) on immune cells. By selectively depleting pathological myeloid cells and T lymphocytes that drive the cytokine storm and disease severity, ELA026 has the potential to reset the hyperinflammatory cascade at its source.
The first-in-class monoclonal antibody has achieved significant regulatory recognition, becoming the first investigational therapy to receive both U.S. Food and Drug Administration Breakthrough Designation and European Medicines Agency Priority Medicines designation for sHLH (search), reflecting its potential to address this life-threatening condition with significant unmet medical need.
SURPASS Trial Advances Pivotal Development
The SURPASS Phase 2/3 pivotal clinical study, presented by Dr. Swaminathan Iyer from MD Anderson Cancer Center, is evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of ELA026 in newly diagnosed, treatment-naïve adult and pediatric patients with sHLH (search). The study is actively enrolling at academic medical centers across the U.S. and Europe.
"We are delighted to connect with the scientific community at ASH and share the clinical development progress of ELA026 in sHLH (search)," said Kim-Hien Dao, DO, PhD, Chief Medical Officer of Electra Therapeutics (search). "Every day, patients with sHLH around the world face a devastating prognosis and very limited treatment options. We are committed to generating pivotal data to demonstrate ELA026's potential to meaningfully improve outcomes for these patients."
Real-World Data Reveals Devastating Disease Burden
A second presentation by Dr. Catherine Broome from MedStar Georgetown University (search) and Dr. Daniel Hausrath from Vanderbilt University Medical Center, in collaboration with EpidStrategies (search), shared results from an Electra-sponsored natural history study characterizing the disease burden and unmet need in patients with sHLH (search).
The comprehensive analysis identified a cohort of 232 adult patients over a 16-year period through electronic health record queries to assess prognostic factors, clinical features, treatment patterns, healthcare utilization, and survival outcomes. The study underscored the life-threatening nature of sHLH (search), its high mortality, and the limited effectiveness of currently available therapies, reinforcing the significant unmet need for improved treatment options.
Critical Unmet Medical Need
Secondary hemophagocytic lymphohistiocytosis (search) is a rare, life-threatening hyperinflammatory disease with a lack of treatment options. It can be triggered by cancer, infection, autoimmune disease, or immunotherapy, and is associated with a severe inflammatory response that requires immediate intervention. Without effective treatment, patients may experience multiorgan failure and death.
The disease is associated with high mortality early in the disease course, with malignancy-associated HLH (search) (mHLH (search)) patients having a mortality rate of approximately 50% at two months with available therapies. This stark statistic emphasizes the urgent need for more effective therapeutic interventions.
Expanding Pipeline in Immunology
Beyond ELA026, Electra Therapeutics (search) is advancing a second SIRP (search)-targeted program, ELA822 (search), designed to selectively deplete activated T lymphocytes, with broad potential across immunology and inflammation. The clinical-stage biotechnology company continues to pioneer therapies against novel targets for diseases in immunology and cancer, positioning itself at the forefront of innovative treatment approaches for challenging medical conditions.